Pharvaris (NASDAQ:PHVS) Stock Price Up 5.3% – What’s Next?

Pharvaris (NASDAQ:PHVS)’s stock price rose 5.3% during mid-day trading on Tuesday . The company traded as high as $19.84 and last traded at $19.34. Approximately 6,321 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 46,693 shares. The stock had previously closed at $18.36.

Pharvaris Stock Performance

The firm has a 50 day moving average price of $19.40 and a two-hundred day moving average price of $19.35. The company has a market cap of $1.01 billion, a P/E ratio of -6.90 and a beta of -3.06.

Hedge Funds Weigh In On Pharvaris

Several large investors have recently modified their holdings of PHVS. Deerfield Management Company L.P. Series C boosted its holdings in Pharvaris by 31.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock worth $26,269,000 after buying an additional 335,687 shares during the period. Novo Holdings A S raised its stake in shares of Pharvaris by 47.7% during the 2nd quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock valued at $32,430,000 after purchasing an additional 556,970 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Pharvaris during the 3rd quarter worth about $906,000. HighVista Strategies LLC boosted its stake in Pharvaris by 35.9% in the 3rd quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock worth $422,000 after purchasing an additional 6,018 shares during the period. Finally, Patient Square Capital LP purchased a new position in Pharvaris during the 3rd quarter valued at about $4,488,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.